Nomura Holdings, Inc.

NYSE:NMR

Financial - Capital Markets

Financial Services
$9.23 -1.32%

-$0.12 today

Market cap
$27.29B
Beta
0.61
P/E (TTM)
0.3
EPS (TTM)
$4,986.67
Dividend yield
3.55%
52W Low $6.02High $9.58

Volume 3.51M

Average 1.75M

NMR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nomura Holdings, Inc.NYSE: NMR

Research & Development · Q1 FY2027 · quarter ended Jun 2026

Research & development remains negative

Q1 FY2027 research & development was ¥0, compared with ¥0 a year earlier. Trailing-twelve-month research & development was ¥0.

Context

  • Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near ¥0 or moves back toward the trailing-twelve-month quarterly average of ¥0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
¥0— QoQ
Last fiscal yearMar 2026
¥0— YoY
LTMJun 2026
¥0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

JPY · from the income statement

Latest · FY2026
0 JPY
Year-over-year change
—

Research & Development vs competitors

How NMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Research & development amounts to 0.0% of revenue for NMR, versus a peer median of 0.0%.
NMR Competitors
Research & Development for NMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NMRNomura Holdings, Inc.LTM Jun 2026¥0 JPY——0.0%
MSMorgan StanleyLTM Sep 2026$0 USD——0.0%
GSThe Goldman Sachs Group, Inc.LTM Sep 2026$0 USD——0.0%
UBSUBS Group AGLTM Jun 2026$0 USD——0.0%
EVREvercore Inc.LTM Jun 2026$0 USD——0.0%
SFStifel Financial Corp.LTM Sep 2026$0 USD——0.0%
LAZLazard LtdLTM Sep 2026$0 USD——0.0%
OPYOppenheimer Holdings Inc.LTM Mar 2026$0 USD——0.0%
JEFJefferies Financial Group Inc.LTM Aug 2026-$221.52M USD-174.6%—1.8%
Peer median (excluding NMR) —-174.6%—0.0%

Competitors are the stored peer set for NMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

JPY
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue1.37T2.3T3.97T4.51T4.76T
Cost of Revenue230.11B1.15T2.6T2.84T2.59T
Gross Profit1.14T1.14T1.38T1.66T2.17T
Gross Margin83.3%49.9%34.7%36.9%45.6%
Research & Development00000
Selling, General & Admin529.51B605.79B673.52B732.39B1.37T
Operating Expenses917.09B995.5B1.1T1.19T1.63T
Depreciation & Amortization59.52B61.42B61.34B61.65B68.27B
EBITDA286.15B210.9B335.19B533.62B608.09B
EBITDA Margin20.8%9.2%8.4%11.8%12.8%
Operating Income226.62B149.47B273.85B471.96B539.82B
Operating Margin16.5%6.5%6.9%10.5%11.3%
Interest Income284.22B1.11T2.62T2.93T2.67T
Interest Expense230.11B1.15T2.6T2.84T2.59T
Other Income / Expenses00000
Income Before Tax226.62B149.47B273.85B471.96B539.82B
Pre-Tax Margin16.5%6.5%6.9%10.5%11.3%
Income Tax Expense80.09B57.8B96.63B124.71B165.44B
Net Income143B92.79B165.86B340.74B362.13B
Net Margin10.4%4.0%4.2%7.6%7.6%
EPS (Basic)46.6830.8654.97115.30123.08
EPS (Diluted)45.2329.7452.75111.03118.99
Weighted Avg Shares3.06B3.01B3.02B2.96B2.94B
Weighted Avg Shares (Diluted)3.16B3.11B3.14B3.07B3.04B

Nomura Holdings, Inc.

NYSE:NMR

Intrinsic Alpha fair value

Locked

Current Price

$9.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.